Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TM5614 PAI-1 Inhibitor Anti-Aging Study in Older Adults with Stable Chronic Diseases
jRCTs021250011Completed
- Sponsor
- Renascience
- Start
- Aug 2025
- Modality
- Drug Delivery Systems
- Countries
- 1
01
Overview
Open-label, single-arm trial of TM5614 in hypertension (HTN), type 2 diabetes mellitus (T2DM), chronic kidney disease (CKD) and 1 more, sponsored by Renascience. Primary endpoint: Primary: Immune cell surface markers by FACS. Started Aug 2025; status: completed.
02
Drugs
TM5614
03
Conditions
hypertension (HTN)type 2 diabetes mellitus (T2DM)chronic kidney disease (CKD)hyperlipidemia
Beyond the preview
Go deeper on jRCTs021250011.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs021250011.